Wednesday, May 17, 2023 2:38:23 PM
Some good posts on Ai stories this looks like another one to review
I have been tracking the press releases and see their new president having many US exits and now leading this company.
Couple of write ups and now hired IR and trading plus a new contract… looks like it’s emerging…
Trading wise: the volume has been picking up the past few weeks so interest seems to be there
https://investorintel.com/technology/netramark-is-unleashing-the-power-of-artificial-intelligence-to-revolutionize-the-pharmaceutical-industry/
https://cdn.jwplayer.com/previews/JCpbGyOr
About Company
NetraMark is a company focused on being a leader in the development of Artificial Intelligence (AI) / Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously.
This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI / ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and / or efficacy of treatment.
President
Highlights of Mr. Spiegel's Incredible Track Record Josh was the Vice President of Business Strategy at VeraSci where he leveraged his experience to provide strategic planning and oversight of commercial operations, including the launch of the Pathway Clinical platform and positioned the company for a highly successful $330M USD exit to WCG Clinical, a leader in the pharmaceutical services sector. He was previously the consulting Vice President of Finance at Prevail Therapeutics, which was later acquired by Eli Lilly. Further, he was a founding partner and Principal at Cypress Associates LLC, a New York based Investment Banking firm, where he was responsible for a broad range of transactions including mergers and acquisitions, restructurings, and equity offerings. Before co-founding Cypress, Mr. Spiegel was an Investment Banking Analyst in the technology group at CBC World Markets. He received his BA in Economics and Public Policy from Duke University and holds the Chartered Financial Analyst® designation
Recent AINMF News
- Will New Trial Solution Data Spark a Rally for this Dual-Listed Gen AI Clinical Trial Leader? • AllPennyStocks.com • 02/29/2024 03:00:00 PM
- Using Gen AI and ML to Improve Clinical Trials for Pharma Companies • AllPennyStocks.com • 02/12/2024 04:20:00 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM